abiraterone has been researched along with Local Neoplasm Recurrence in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (77.27) | 24.3611 |
| 2020's | 5 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, T; Koie, T; Miyake, H; Naiki, T; Nakane, K; Shiroki, R; Sugiyama, Y; Takahara, K; Yasui, T | 1 |
| Abdel-Gawad, O; Atawia, IM; Gupta, S; Kushwaha, PP; Lin, S; Shankar, E; Verma, S | 1 |
| Berlin, D; Chin, JLK; Fernandes, R; Finelli, A; Fleshner, NE; Hamilton, RJ; Hansen, AR; Herrera-Caceres, JO; Hersey, K; Joshua, AM; Kenk, M; Kulkarni, GS; Lajkosz, K; Moussa, M; Sayyid, RK; Sridhar, S; Sweet, J; van der Kwast, T; Veloso, R; Winquist, E; Zlotta, AR | 1 |
| Higa, J; Larsen, C; Savino, S; Scholz, M; Vogelzang, N; Wilenius, K | 1 |
| Beriwal, S; Rodríguez-López, JL | 1 |
| Culig, Z; Eder, I; Eigentler, A; Handle, F; Heidegger, I; Hoefer, J; Klocker, H; Kroon, J; Leo, A; Ploner, C; Puhr, M; Schaefer, G; Van der Pluijm, G | 1 |
| Agrawal, M; Almeida, F; Brown, A; Dicker, AP; Fernandez, DC; Garcia, JA; Gratt, J; Iagaru, A; Lutzky, J; Morris, MJ; Petrenciuc, O; Sartor, O; Shore, ND; Smith, MR; Sweeney, C; Vogelzang, NJ; Wong, YN | 1 |
| Dowsett, M; Folkerd, E; Johnston, SR; Liccardi, G; Martin, LA; Nikitorowicz-Buniak, J; Pancholi, S; Ribas, R; Simigdala, N | 1 |
| Alva, AS; Cao, X; Chinnaiyan, AM; Delekta, A; Jing, X; Juckette, KM; Kim, Y; Luo, E; MacLeod, AR; Parolia, A; Qiao, Y; Shukla, S; Su, F; Tan, M; Tien, JC; Vo, J; Wang, L; Wang, X; Xiao, L; Xu, A; Zhang, Y; Zheng, H | 1 |
| Arai, S; Balk, SP; Bhasin, M; Bhasin, SS; Calagua, C; Corey, E; Gao, C; Montgomery, B; Mostaghel, EA; Nelson, PS; Russo, JW; Taplin, ME; Voznesensky, OS; Ye, H | 1 |
| Eto, M; Inokuchi, J; Kobayashi, T; Namitome, R; Shiota, M; Tatsugami, K | 1 |
| Allan, AL; Annala, M; Basappa, NS; Beja, K; Chi, KN; Eigl, BJ; Ellard, SL; Finch, D; Gregg, RW; Hotte, SJ; Joshua, AM; Kollmannsberger, C; Macfarlane, RJ; North, S; Powers, J; Ruether, JD; Salim, M; Seymour, L; Tinker, A; Torri, V; Tu, D; Winquist, EW; Wyatt, AW | 1 |
| Dahut, WL; Madan, RA | 1 |
| Castellano, D; Daugaard, G; De Porre, P; Galli, L; Garrido, JM; Géczi, L; George, DJ; Goon, B; Hotte, SJ; Lee, E; Londhe, A; Mainwaring, PN; McGowan, T; Molina, A; Naini, V; Saad, F; Souza, C; Sternberg, CN; Tay, MH; Todd, MB | 1 |
| Bristow, RG; Dal Pra, A; Locke, JA; Supiot, S; Warde, P | 1 |
| Antonarakis, ES; Carducci, MA; Chen, Y; Eisenberger, MA; Lu, C; Luo, J; Nakazawa, M; Paller, CJ | 1 |
| Plymate, S; Sprenger, C; Uo, T | 1 |
| Benoist, GE; Gerritsen, WR; Kramers, C; Mulders, PF; Schers, HJ; van Erp, PH; Westdorp, H | 1 |
| Abderrahman, B; Bhattacharya, P; Fan, P; Hawsawi, YM; Jordan, VC; Maximov, PY; Pokharel, N | 1 |
| Albiges, L; Attard, G; Bianchini, D; de Bono, J; Fizazi, K; Loriot, Y; Massard, C; Mateo, J; Mehra, N; Petrylak, DP; Pezaro, C; Ryan, CJ; Shen, L; Varga, A | 1 |
| Concepcion, RS; Crawford, ED; Finkelstein, SE; Gomella, LG; Keane, TE; Koo, PJ; O'Sullivan, JM; Petrylak, DP; Saad, F; Shore, N; Sieber, P; Slovin, SF; Stone, NN; Tombal, B; Vogelzang, NJ; Yu, EY | 1 |
| Börgermann, C; Molitor, B | 1 |
4 review(s) available for abiraterone and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Synergistic action of image-guided radiotherapy and androgen deprivation therapy.
Topics: Androgen Antagonists; Androstenes; Benzamides; Biomarkers; Combined Modality Therapy; Dose-Response Relationship, Radiation; Flutamide; Goserelin; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiotherapy, Image-Guided; Risk Assessment; Treatment Outcome | 2015 |
[Hormone therapy in prostate cancer; a pharmacotherapeutic challenge].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Disease Progression; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone; Treatment Outcome | 2015 |
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).
Topics: Androgens; Androstenes; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2017 |
[Second line therapy for castration-resistant prostate cancer (CRPC)].
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Recurrence, Local; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Survival Rate; Taxoids; Tissue Extracts | 2012 |
5 trial(s) available for abiraterone and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.
Topics: Abiraterone Acetate; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 2023 |
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms; Nitriles; Phenylthiohydantoin; Prognosis; Radium; Survival Rate | 2018 |
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Canada; Disease Progression; Gonanes; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Survival Analysis; Treatment Outcome | 2019 |
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisolone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Treatment Outcome | 2014 |
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
13 other study(ies) available for abiraterone and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Androstenes; Anilides; Antineoplastic Combined Chemotherapy Protocols; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds | 2022 |
Inhibition of Wnt/β-catenin pathway overcomes therapeutic resistance to abiraterone in castration-resistant prostate cancer.
Topics: beta Catenin; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2023 |
Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Combined Modality Therapy; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radiosurgery; Retrospective Studies; Tissue Extracts | 2020 |
Nodal Recurrence From Prostate Adenocarcinoma: Curable or Incurable?
Topics: Adenocarcinoma; Androstenes; Carboxylic Acids; Combined Modality Therapy; Cyclobutanes; Gonadotropin-Releasing Hormone; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Irradiation; Male; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms | 2020 |
The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.
Topics: Androgen Antagonists; Androstenes; Benzamides; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Kaplan-Meier Estimate; Male; MCF-7 Cells; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Glucocorticoid | 2018 |
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
Topics: Androstenes; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Receptors, Androgen; Signal Transduction; Tamoxifen | 2018 |
Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstenes; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Humans; Male; Mice; Mice, SCID; Neoplasm Recurrence, Local; Neoplasm Transplantation; Nitriles; Oligonucleotides, Antisense; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction | 2018 |
Downregulation of
Topics: Alternative Splicing; Androgen Antagonists; Androstenes; Animals; Benzamides; Cell Line, Tumor; Dipeptidyl Peptidase 4; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Neoplasm Recurrence, Local; Neoplasm Transplantation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Sitagliptin Phosphate | 2018 |
Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Biopsy, Large-Core Needle; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Orchiectomy; Prognosis; Progression-Free Survival; Prostate; Prostatic Neoplasms; Retrospective Studies; Risk Assessment | 2019 |
Real-world experience with abiraterone.
Topics: Androstenes; Androstenols; Humans; Male; Neoplasm Recurrence, Local; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2014 |
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2015 |
Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?
Topics: Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Humans; Male; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Protein Isoforms; Receptors, Androgen; Treatment Outcome | 2015 |
Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Female; Humans; Incidence; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Quality of Life; Receptors, Estrogen; Survival Rate; Tamoxifen | 2016 |